Inhibition of EGFR has been reported to be beneficial in improving insulin resistance and type 2 diabetes, attenuating diabetic nephropathy and kidney fibrosis, inhibiting cardiac hypertrophy and heart failure, and reducing atherosclerosis and elevated arterial blood pressure in experimental animal models 9, 13, 26, 27. The gene discussed is EGFR; the disease is cardiac hypertrophy.